Forbion Capital Partners
Overview
Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing drugs and technologies, with a clear focus on product development. The Forbion team is specialized in the evaluation of late stage preclinical / early stage clinical development programs. Forbion also invests in medical device companies with a focus on interventional cardiology and gastroenterology. The Forbion team began operating in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December 2006 the group broadened its investor base, became independent, and changed its name to Forbion Capital Partners. Forbion currently has EUR 200 million under management.
Investment Focus
- Innovative biotech companies
- Companies addressing substantial unmet medical needs
- Companies with potential for breakthrough therapies
- Companies with a focus on sustainability and environmental impact
- Companies in the biopharmaceutical space
- Companies in the medical device sector
- Companies in the food, agriculture, materials, and environmental technologies sectors
Portfolio Companies
Reach Forbion Capital Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Forbion Capital Partners
What sectors does Forbion Capital Partners invest in?
Forbion Capital Partners invests in Healthcare, Materials, Agriculture, Pharmaceuticals, Medical Devices and Sustainability, and is based in Naarden, Noord-Holland, Netherlands. Forbion Capital Partners is listed as a vc in the ConnectSafely investor database.
What stage does Forbion Capital Partners invest at?
Forbion Capital Partners backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1.5M - 3M.
Which regions does Forbion Capital Partners invest in?
Forbion Capital Partners invests across United States, United Kingdom, Germany, France, Italy and Denmark.
What companies has Forbion Capital Partners invested in?
Forbion Capital Partners's portfolio includes PanGenetics, EEDEN, enGene, NewAmsterdam Pharma, Novameat, Solasta Bio, Crucell and Rhein Biotech.
How do I contact Forbion Capital Partners?
Forbion Capital Partners's contact details — including phone and LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.
Last updated · Source: ConnectSafely investor database
